tbuckley/cabot-search huggingface dataset:
THU0572-HPR Osteomalacia: Developing an Interactive Education Tool for South Asian Populations
Authors: S. Robinson, A. Adebajo, P. Heliwell, A. Rahman, K. Raza, A. Samanta, M. Johnson, P. Bishop, K. Kumar, D. Walker
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Osteomalacia is a significant population health risk that preferentially affects darker skinned people where English may not be the first language. <h3>Objectives</h3> We were interested to develop an e-based interactive, multi language tool, based on the Mind-Map and giving information in an accessible layered fashion suitable for people with poor English language skills. <h3>Methods</h3> The Mind-Map wasused as the "home" page. Hyperlinks gave the user options to link to more detailed information. It was possible to take any route through the information and to return from any screen to the original Mind-Map screen. The tool was designed to give the user information in layers. The first layers of the tool are the basic knowledge the user requires to make informed decisions and choices. Further layers lead the user to more in depth information and links to the internet. Only the first layer of the tool was translated into Urdu. The translation was reviewed by a panel of six educated Urdu speakers in the UK to ensure that the translation was correct. A focus group of 10 Urdu speakers from Stourbridge was used to test the tool. A presentation using the tool was performed and their reactions to it recorded. The participants were given the DVD to take away with them. Two months later the group was reconvened and the discussion recorded and transcribed. <h3>Results</h3> All participants felt that they had learned a lot about Osteomalacia. There was a feeling that this was a very important issue and they were surprised how little they knew about it. The content was judged to be of appropriate detail. It was felt that only the first layer would be used in a presentation but some users may be interested in having more information. It was also suggested that presenting it in English to encourage people to speak enough English to interact with healthcare professionals would be helpful. There were suggestions on how this should be used with presentations in communities but also in schools. They felt that this was a community tool rather than just hospital based. One participant had already given presentations to their community and reported very good informal feedback. <h3>Conclusions</h3> We have produced a bi-lingual interactive tool to educate people about Osteomalacia and its treatment. Initial reactions show it to be suitable for the intended audience. We now intend to study this for knowledge transfer and change of behaviour. <h3>Acknowledgements</h3> We would like to acknowledge the contribution of the focus group from Stourbridge Birmingham. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4424
Aortic Dissection Causing a Unilateral Perfusion Defect on Lung Scintigraphy
Authors: AMIT N. SANGHVI, DANIEL T. MYERS, JUDITH M. JOYCE
Journal: Clinical Nuclear Medicine (2003)

From the Nuclear Medicine Section, Department of Radiology, The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania Received for publication March 28, 2002. Revision accepted July 8, 2002. Correspondence: Amit N. Sanghvi, Nuclear Medicine Section, Department of Radiology, The Western Pennsylvania Hospital, 4800 Friendship Avenue, Pittsburgh, Pennsylvania 15224. E-mail [email protected]
Early-Stage Hodgkin's Lymphoma
Authors: Michele Bibas, Andrea Antinori
Journal: New England Journal of Medicine (2010)

To the Editor: We think that the paragraph on infection with the human immunodeficiency virus (HIV) in the review article by Armitage (Aug. 12 issue)1 requires some important corrections and clarifications. First, according to the classification of the Centers for Disease Control and Prevention, Hodgkin's lymphoma is one of the conditions that does not define the acquired immunodeficiency syndrome (AIDS), not, as Armitage indicates, one of the defining illnesses of AIDS.2 Second, although we agree that today HIV-infected patients with early-stage Hodgkin's lymphoma should receive the same combinations of chemotherapy and radiotherapy as patients who are not infected with HIV, . . .
Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma.
Authors: Jennifer Schlegel, Maria Sambade, Susan Sather, Stergios Moschos, Aik-Choon Tan, Amanda Winges, Deborah DeRyckere, Craig C. Carson, Dimitri G. Trembath, John J. Tentler, Gail Eckhardt, Pei-Fen Kuan, Ronald L. Hamilton, Lyn M. Duncan, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Bentley R. Midkiff, Xiaodong Wang, Jing Liu, Weihe Zhang, Chao Yang, Stephen V. Frye, H. Shelton Earp, Janiel Shields, Douglas K. Graham
Journal: Cancer Research (2013)

Abstract Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. While recent therapeutic advances have prolonged patient survival, prognosis remains dismal. Mer is a receptor tyrosine kinase with oncogenic properties that is often overexpressed or activated in various malignancies. Using both protein immunohistochemistry and microarray analyses, we demonstrate that Mer expression correlates with disease progression. Mer expression was highest in metastatic melanomas followed by primary melanomas whereas the lowest expression was observed in nevi. In addition, over 50% of melanoma cell lines overexpressed Mer compared to normal human melanocytes, however overexpression did not correlate with mutations in BRAF or RAS. Stimulation of melanoma cells with the Mer ligand Gas6 resulted in activation of several downstream signaling pathways including MAPK/ERK, PI3K/Akt, and Jak/STAT. Mer inhibition via shRNA reduced Mer-mediated downstream signaling, reduced colony formation by up to 59% (p&amp;lt;0.05) and diminished tumor volume by 60% (p&amp;lt;0.05) in a human melanoma xenograft murine model. Treatment of melanoma cells with UNC1062, a novel Mer-selective small molecule tyrosine kinase inhibitor, reduced activation of Mer-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar and inhibited invasion of melanoma cells. In addition, Mer inhibition synergized with mutant BRAF inhibition in signaling and apoptosis assays. This work establishes Mer as a therapeutic target in melanoma and provides rationale for the continued development of Mer-targeted therapies. Citation Format: Jennifer Schlegel, Maria Sambade, Susan Sather, Stergios Moschos, Aik-Choon Tan, Amanda Winges, Deborah DeRyckere, Craig C. Carson, Dimitri G. Trembath, John J. Tentler, Gail Eckhardt, Pei-Fen Kuan, Ronald L. Hamilton, Lyn M. Duncan, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Bentley R. Midkiff, Xiaodong Wang, Jing Liu, Weihe Zhang, Chao Yang, Stephen V. Frye, H. Shelton Earp, Janiel Shields, Douglas K. Graham. Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3037. doi:10.1158/1538-7445.AM2013-3037
Case 33-2002
Authors: Stuart B. Mushlin, Jeffrey M. Drazen, Martin A. Samuels, Eugene J. Mark
Journal: New England Journal of Medicine (2002)

Presentation of CaseA 28-year-old woman was admitted to the hospital because of ocular inflammation, fever, and headache.The patient had been well until three weeks earlier, when a cough developed, initially productive of yellow sputum, with rhinorrhea and a sore throat. The symptoms continued for about two weeks and were not affected by amoxicillin. About one week before admission, fever developed, and the patient's temperature rose as high as 40.6°C; the cough continued but became nonproductive. A rash was noted intermittently in both axillae, and the right axilla became reddened. About five days before admission, a frontal headache developed . . .
PTU-062 Value of MRI in Predicting Severe outcome in Small Bowel Crohn’S Disease: Abstract PTU-062 Table
Authors: C Rutter, S Bhatt, I Sequeiros, P Burn, P D Thomas
Journal: Gut (2013)

<h3>Introduction</h3> The optimal approach to managing terminal ileal (TI) Crohn’s disease remains to be defined. It is unclear at what stage surgery or biological therapy should be offered and current clinical and biochemical parameters offer poor prediction of disease course. Small bowel MRI scanning (SBMRI) has been correlated with endoscopic and histological disease severity in Crohn’s disease and may offer better global assessment of the extent and severity of disease. We aimed to determine which MRI features might predict the need for surgery or biological therapy. <h3>Methods</h3> 48 sequential patients with Crohn’s disease who underwent SBMRI in a 20 month period to Feb 2011 were identified from a radiological database. 8 patients were excluded due to predominant colonic disease. All remaining 40 patients had confirmed isolated TI disease. Standard management with escalation of therapy via immunomodulors, biological agents and surgery based on clinical follow up was applied. Patients were followed for a minimum of 2 years after the initial MRI. MRI scanning was performed using oral fluid load, IV buscopan, T1/2 axial, coronal and dynamic post contrast sequences. The images were reviewed by a radiologist blinded to outcome of cases and key abnormal features recorded (mesenteric abnormalities, wall thickness &gt; 6 mm, disease extent &gt; 15 cm or proximal dilatation &gt; 25 mm). Patients were then divided into 2 groups, those requiring biological therapy or surgery (severe) and those managed with 5ASA or immunomodulators alone (non severe). <h3>Results</h3> The characteristic of the two groups is shown in the table. Means given unless stated. 6/20 patients in the non-severe group (A) had two or more adverse radiological features compared with 12/20 in the severe (B) group (p = 0.06). However, only 3/20 patients had lumen &gt; 25 mm or extent &gt; 15 cm in A compared with 15/20 in B (p &lt; 0.001). Wall thickness and mesenteric involvement were not associated with a severe outcome. Disease extent and proximal luminal diameter were significantly associated with surgery (p = 0.02 and p = 0.0001). 85% of patients who eventually required surgery had either proximal lumen &gt; 25 mm or disease extent &gt; 15 cm. <h3>Conclusion</h3> Two or more adverse radiological MRI features are associated with with the need for surgery or biological therapy. Small bowel dilatation &gt; 25 mm proximal to the disease segment and disease extent &gt; 15 cm are particularly associated with the need for surgery. These MRI findings may be helpful in deciding appropriate longer term strategies for managing these patients. <h3>Disclosure of Interest</h3> None Declared
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
Authors: Andrea Varga, Sarina Anne Piha-Paul, Patrick Alexander Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Elizabeth A. Johnson, Jonathan D. Cheng, Sammy Yuan, Eric H. Rubin, Daniela E. Matei
Journal: Journal of Clinical Oncology (2015)

5510 Background: Pembrolizumab is a potent, highly selective humanized monoclonal antibody against PD-1 designed to block interaction with PD-L1 and PD-L2 and remove the inhibition of T-cell activation against cancer. PD-L1 was found to be overexpressed in ovarian cancer and can contribute to malignancy. We assessed the safety and efficacy of pembrolizumab in pts with PD-L1+advanced ovarian cancer. Methods: KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort phase Ib trial of pembrolizumab in pts with PD-L1+ advanced solid tumors. Key eligibility criteria for the ovarian cancer cohort included advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of prior therapy; PD-L1 expression in ≥ 1% of cells in tumor nests or PD-L1+ bands in stroma as determined by a prototype IHC assay at a central laboratory; and ECOG PS 0-1. Pembrolizumab 10 mg/kg was given every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Primary end points: safety, tolerability, and preliminary efficacy. Response assessed per RECIST v1.1 by investigators every 8 weeks for the first 6 months and every 12 weeks thereafter. Results: 26 pts were enrolled. Mean (SD) age was 58.1 (7.5); 57.7% were white. 84.6% received prior therapies for recurrent/metastatic disease (38.5% received ≥ 5 therapies), and 50% received prior adjuvant therapies. One pt achieved complete response and 2 pts experienced partial response; 6 pts had stable disease. Of the 3 patients who responded, all remain in response with duration of response ≥ 24 weeks at the time of analysis. The best overall (confirmed) response was 11.5% (95% CI, 2.4-30.2). 6/26 (23.1%) had evidence of tumor reduction; 3 had a tumor reduction of at least 30%. All pts experienced ≥ 1 adverse event (AE) (regardless of treatment); most common were fatigue (42.3%), anemia (30.8%), and decreased appetite (30.8%). Drug-related AEs occurred in 69.2% of pts (grade ≥ 3, 1/26 pts). Currently, 6 pts remain on pembrolizumab treatment. Conclusions: PD-1 blockade with pembrolizumab is well tolerated and has antitumor activity in pts with advanced ovarian cancer. This preliminary signal for clinical efficacy will be further investigated. Clinical trial information: NCT02054806.
Abstract LB-369: A novel aniline derivative enhances radiosensitivity of lung cancer through suppression of Nrf2 activity
Authors: Jiyeon Ahn, Saelooom Lee, Min-Jin Lim, Mi-Hyoung Kim, Chi-Ho Yu, Yeon-Sook Yun, Jie-Young Song
Journal: Cancer Research (2011)

Abstract The major obstacle in radiotherapy or chemotherapy is the resistance of cancer cells to the therapies. Nuclear factor erythroid-2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that regulates antioxidant enzymes. Kelch-like ECH-associated protein (Keap1) sequesters Nrf2 and leads to proteasomal degradation of Nrf2 in non-stressed condition. Keap1 is often found with biallelic mutation in non-small cell lung cancer (NSCLC) cell lines and NSCLC patients, results in constitutive activation of Nrf2 function, and contributes to resistance to anticancer drugs. Therefore, we aimed to develop small molecules that inhibit Nrf2 activity to maximize radiation-induced cell death via increasing ROS generation. A cell-based high-throughput screening using luciferase assay, we have identified an aniline derivative (IM3829) as a radiosensitizer of lung cancer in vitro and in vivo. In clonogenic assay, this compound sensitized H1299 lung cancer cells to irradiation. IM3829 with irradiation significantly increased ROS accumulation compared with radiation alone treated cells, leading to apoptotic cell death synergistically. IM3829 inhibited Nrf2 binding activity and HO-1 expression. In H1299 xenografts mice, IM3829 with radiation significantly inhibits tumor growth by 47 % and 27 % compared with vehicle or radiation alone treated animals, respectively. Our finding suggested that IM-3829 could be a promising radiosensitizer in lung cancer patients, particularly those with a high expression of Nrf2. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-369. doi:10.1158/1538-7445.AM2011-LB-369
DISECCIÓN SUBMUCOSA ENDOSCÓPICA EN NEOPLASIAS GÁSTRICAS PRECOCES: EVOLUCIÓN Y COMPLICACIONES A CORTO PLAZO DE LA FASE INICIAL DE LA CURVA DE APRENDIZAJE
Authors: JC Marín-Gabriel, J Díaz Tasende, P Hernán-Ocaña, A González-Blanco, S Rodríguez Muñoz, AJ Del Pozo García, M Alonso-Riaño, F Colina-Ruizdelgado, M Pérez Carreras, A Domínguez-Rodríguez, G Castellano Tortajada
Journal: Endoscopy (2013)

Introducción: La disección submucosa endoscópica es una técnica de reciente introducción en nuestro país. Objetivos: Recopilar la evolución y complicaciones, a corto plazo. Material y Métodos: Se recogieron de forma prospectiva 15 lesiones resecadas en el Hospital Universitario 12 de Octubre de Madrid y 1 realizada en el Hospital Sanitas La Moraleja. Resultados: Se llevaron a cabo 16 D.S.E.s entre septiembre de 2008 y junio de 2013. La mediana de edad fue de 75 años (46 – 86). La mediana de tamaño de las lesiones fue de 22,5 mm (10 – 35). Las lesiones estaban localizadas en fundus (1; 6,3%), cuerpo (4; 25%) y el resto en antro o incisura (11; 68,8%). La morfología más frecuente fue la IIa+IIc (9; 56,2%), seguida de las IIa (2; 12,5%) y Is+IIa (2; 12,5%). Se logró la exéresis en bloque en 10 casos (62,5%), todos ellos R0. El estudio histológico mostró neoplasia mucosa de alto grado en 13 casos (81,25%). En 1 de las lesiones (6,25%) se identificó invasión s.m. < 500µ por lo que no se recomendó tratamiento quirúrgico complementario. Se detectó 1 enfisema gástrico (6,25%). En este paciente, con importante comorbilidad asociada, se produjo el exitus en los días siguientes por sepsis secundaria a neumonía nosocomial. Se detectaron 2 casos de hemorragia digestiva (12,5%), resueltos con tratamiento endoscópico y sin requerimientos transfusionales. El ingreso se prolongó una mediana de 4 días (rango: 3 – 8) debido a las complicaciones. Conclusión: La escasa posibilidad de entrenamiento con lesiones gástricas en nuestro medio, probablemente, da lugar a resultados iniciales en los que los porcentajes de resecciones en bloque y R0 son inferiores a lo esperado. La morbilidad asociada, al inicio de la curva de aprendizaje, no dista de la descrita en otros países europeos.
SAT0343 Patients with Osteoarthritis are More Satisfied Following Multidisciplinary Care than Usual Outpatient Care at 4 Month Follow-Up – a Randomised Controlled Trial
Authors: R. H. Moe, M. Grotle, I. Kjeken, I. C. Olsen, P. Mowinckel, E. A. Haavardsholm, K. B. Hagen, T. K. Kvien, T. Uhlig
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Osteoarthritis (OA) is one of the most frequent chronic musculoskeletal disorders, and one of the leading causes of pain and disability. Evidence-based recommendations mostly consider single interventions, however in clinical practice, combinations of different interventions are often used, but with little evidence for their effectiveness. <h3>Objectives</h3> To examine the efficacy of a multidisciplinary outpatient clinic, including a brief group-based educational programme, compared to an individual outpatient clinic for patients with hand, hip, knee or generalized OA after 4 months. <h3>Methods</h3> Patients referred to a specialized rheumatology outpatient clinic with a clinical OA diagnosis were randomised to a 3.5h brief multidisciplinary group-based educational intervention followed by individual consultations, or to usual individual care. Demographic variables included age, gender, and body mass index (BMI). Primary outcome was satisfaction with the health service, evaluated on a NRS with anchors 0=extremely unsatisfied and 10=extremely satisfied. Secondary outcomes included pain, fatigue, and stiffness (NRS, 0-10), Hopkins Symptom Checklist-25 (HSCL-25, 1-4, 1 is best), Arthritis Self-Efficacy Scales (ASES, 10-100, 100 is best), Western Ontario and McMaster- (WOMAC) (0-30, 0 is best) and Australian/Canadian hand- (AUSCAN) (0-10, 0 is best) osteoarthritis indexes. <h3>Results</h3> Of 390 patients, 86.4 % (n=337) were women, and mean (SD) age was 63.1 (8.0) years. Patients who received a multidisciplinary intervention were more satisfied with the health service, compared to controls after 4 months, with a mean difference (NRS) of -1.05 (CI -1.68;-0.43) (p&lt;0.001). Among secondary outcomes, self-efficacy with other symptoms improved significantly compared to controls by 3.54 vs. -1.12 units (p=0.02). There were no differences in other secondary outcomes using mixed model analyses between groups at 4-month follow-up. <h3>Conclusions</h3> Patients with OA receiving a brief multidisciplinary intervention were more satisfied with health care than controls receiving individual outpatient care. These findings support the role of multidisciplinary care in the treatment of OA. <h3>Disclosure of Interest</h3> None Declared
“Pay for Delay” Settlements of Disputes over Pharmaceutical Patents
Authors: Aaron S. Kesselheim, Lindsey Murtagh, Michelle M. Mello
Journal: New England Journal of Medicine (2011)

Pay-for-delay settlements involve payments by manufacturers of brand-name drugs to manufacturers of generic drugs in exchange for a delay in the marketing of generic drugs. This report discusses the legal and economic implications of pay-for-delay settlements.
Abstract IA3: Discovery in cancer genomics by next-generation sequencing and data analysis
Authors: Elaine Mardis
Journal: Cancer Research (2011)

Abstract The combined use of next-generation sequencing and advanced analytical approaches has transformed our view of the cancer genome. Not only has large-scale characterization of the genomes of tumors been informative but we also can produce important companion datasets of expressed RNAs and of methylation sites, and then integrate these data to obtain a fuller picture of tumor biology. Scaling these methods and analyses to investigate hundreds of tumors with shared tissues of origin has enabled an appreciation of the multitude of genes that can be impacted by various forms of alteration from point mutations through gross structural changes, along with a pathways-based understanding of somatic alterations. The availability of extensive clinical data allows correlation of specific alterations to clinical outcomes, response to therapy and other critically important factors that enable the translation of genomic discoveries into clinical practice. My talk will survey the different data-driven approaches currently being applied to tumor:normal pairs, then discuss results from whole genome sequencing and analysis of large numbers of breast tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr IA3.
Lifestyle Risk Factors for Allergic Rhinitis in Schoolchildren: Are Sports Activities a Negative Factor?
Authors: Jiro Takeuchi, Takashi Kusunoki, Takeshi Morimoto, Mio Sakuma, Kumiko Mukaida, Takahiro Yasumi, Ryuta Nishikomori, Toshio Heike
Journal: Journal of Allergy and Clinical Immunology (2013)
Cutaneous Sarcoidosis Evaluated by FDG PET
Authors: Yuxin Li, Gholam R. Berenji
Journal: Clinical Nuclear Medicine (2011)

A 50-year-old man presented with initial complaints of diffuse skin pain and pruritus. Physical examination revealed scattered skin plaques and subcutaneous nodules with mild tenderness throughout the body. Skin biopsy demonstrated noncaseating epithelioid granulomas. Patient soon developed cough, fever with hot flashes, and shortness of breath on exertion. FDG PET/CT demonstrated diffuse cutaneous involvement throughout the body. Follow-up FDG PET/CT after treatment revealed a decrease in FDG uptake suggesting a good response to therapy.